• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Ketek (telithromycin) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2010

Summary View



  • colchicine should be avoided in patients receiving Ketek. If Ketek is prescribed in patients with normal kidney and liver function, the dose is colchicine should be reduced. Concomitant treatment with Ketek and colchicine is contraindicated in patients with kidney or liver impairment.
Drug Interactions
  • Colchicine is a substrate for both CYP 3A4 and the efflux transporter, P-glycoprotein (P-gp), and a significant increase in colchicine plasma concentration is anticipated when co-administered with strong CYP 3A4 inhibitors such as telithromycin.


Who should not take Ketek?
  • Do not take Ketek if you: take colchicine (Colcrys®) and have kidney or liver problems